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Increased levels of the inﬂammatory biomarker C-reactive
protein at baseline are associated with childhood sickle cell
vasocclusive crises
Microvessel occlusion, the main pathological process under-
lying the cardinal clinical manifestation of sickle cell disease
(SCD), is frequently termed as vaso-occlusive crisis (VOC) or
pain crisis (Stuart & Nagel, 2004). Since the description of SCD
as a clinical entity nearly a century ago, investigations into the
pathophysiology of VOC have been dynamic and manifold,
leading to the delineation today of a complex process,
encompassing interactions between sickle red blood cells
(RBCs), white blood cells (WBCs), endothelium, plasma
proteins, and several other factors (Frenette & Atweh, 2007).
Additionally, robust laboratory and animal data have further
delineated the roles of hemolysis-related decreased nitric oxide
bioavailability (Reiter et al, 2002), ischaemia-reperfusion
injury (Kaul & Hebbel, 2000), and endothelial activation
(Embury et al, 2004; Belcher et al, 2005) in exacerbating the
microvessel occlusive events of SCD.
Several lines of evidence suggest that SCD is associated with
a chronic inﬂammatory state (Platt, 2000; Belcher et al, 2003).
In recent years there has been great interest in the role of high
sensitivity C-reactive protein (hs-CRP) as a stable plasma
biomarker of low-grade, chronic, systemic inﬂammation in
predicting risk for cardiovascular disease in adults (Koenig
et al, 1999; Ridker et al, 2000; Verma et al, 2005). In this study
we evaluate a panel of biomarkers, including hs-CRP, that are
representative of previously proposed mechanisms of micro-
vessel occlusion-related clinical events in SCD for their
associations with painful episodes in childhood SCD.
We have studied a cohort of children and adolescents with
SCD at baseline, to ascertain if biomarker assessments done
during the clinically silent ‘steady state’ condition correlate
with hospitalization for pain, a signature clinical outcome of
microvessel occlusion and indicator of sub-clinical disease
burden (Platt et al, 1994; Miller et al, 2000). Key biomarkers
from the panel included: total WBC Count and hs-CRP as
markers of systemic global inﬂammatory activity; Haemoglo-
bin (Hb), and lactate dehydrogenase (LDH) as reﬂective of
haemolytic status (Kato et al, 2006);fetal haemoglobin (HbF)
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Several lines of evidence suggest that sickle cell disease (SCD) is associated
with a chronic inﬂammatory state. In this study of 70 children with SCD at
steady state evaluated by a broad panel of biomarkers representing previously
examined mechanisms of pathogenicity in SCD, high sensitivity C-reactive
protein (hs-CRP), a marker of low-grade, systemic inﬂammation, emerged as
the most signiﬁcant laboratory correlate of hospitalizations for pain or vaso-
occlusive (VOC) events. While markers of increased haemolytic status,
endothelial activation and coagulation activation all correlated positively with
VOC events by univariate analysis, baseline hs-CRP levels provided the most
signiﬁcant contribution to the association in multiple regression models
(22%), and, hs-CRP, along with age, provided the best ﬁt in negative
binomial models. These data highlight the clinical relevance of the role of
inﬂammation in paediatric VOC, providing both a rationale for future
therapeutic strategies targeting inﬂammation in microvessel occlusive
complications of SCD, and the potential clinical use of hs-CRP as a
biomarker in childhood SCD.
Keywords: sickle cell disease, inﬂammation, paediatric haematology, vascu-
lar biology.
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(Kato et al, 2005) and sP-selectin (Burger et al 2003; Frenette
et al, 1998) as indices of endothelial activation; prothrombin
fragment F1.2, a marker of thrombin generation, and
D-Dimer, a measure of ﬁbrin formation and dissolution.
Our aim is to measure these laboratory markers at baseline for
an association with the clinical endpoint of acute VOC
requiring hospitalization. Our goal is to add to the current
state of knowledge regarding the clinical signiﬁcance of
laboratory biomarkers with respect to microvessel occlusive
complications of SCD. Iterative validation of such laboratory
biomarkers in the clinical setting would also result in
establishing objective measures of the success or failure of
novel interventions for these complications.
Methods
Patient population
The study population included 70 children with SCD (HbSS,
HbSb
0thalassemia, and HbSC genotype) aged 2–20 years,
evaluated in basal steady state at the time of their ‘routine’
health care maintenance visit to the sickle cell clinic. Patients
were considered to be in steady state if they were afebrile,
asymptomatic with SCD, and had not been hospitalized for at
least 10 d prior to date of blood draw. No patient was on
chronic transfusion therapy. No subject was on hydroxy-
carbamide therapy. Age-matched HbAA controls (3–21 years)
were also included. This study was reviewed and approved by
the Institutional Review Committee for the protection of
human subjects at St Christopher’s Hospital for Children/
Drexel University and Thomas Jefferson University. In accor-
dance with the Declaration of Helsinki, informed consent was
obtained prior to patient blood sampling at the time of
enrollment in these studies. For minors, patient assent where
appropriate, was obtained in addition to parental permission.
A retrospective review was performed on individual patient
records for a discharge diagnosis of painful episode or VOC,
including those complicated by the occurrence of acute chest
syndrome (ACS, chest-wall pain in association with ﬁndings
of a new pulmonary inﬁltrate on chest X-ray ﬁlms and fever
(Charache et al, 1995). Total painful episodes over a cumu-
lative 3-year period including the calendar year of the blood
draw, the year previous to, and the year following date of
blood draw were included in the analyses. Blood was drawn by
a well-trained phlebotomist using a 2-syringe technique.
Blood was collected into appropriate anticoagulant tubes,
platelet-poor plasma was prepared by centrifuging whole
blood at 1500 g for 10 min, aliquots of plasma were stored at
)70 C.
Biomarker assays
Biomarkers were assayed by commercially available enzyme-
linked immunosorbent assay kits as follows: Those pertinent to
inﬂammation and endothelial activation (hs-CRP-ALPCO
Immunoassays Salem, NH, sVCAM1 and sP-selectin; R & D
Systems, Minneapolis, MN, USA); and coagulation activation/
ﬁbrinolysis (prothrombin fragment F1.2-Enzygnost, Dade
Behring Inc. Newark, DE, D-Dimer-Imuclone, American
Diagnostica, Stamford, CT). LDH levels were measured using
an LDH assay kit (TOX07; Sigma Aldrich, St Louis, MO,
USA). The enzyme activity in i/u per litre was read from a
calibration curve generated using an LDH standard (Sigma
Aldrich). Haematological indices (haemoglobin levels, WBC,
and platelet counts) were obtained using a Coulter Counter,
Model StK S. Statistics was performed using Sigmastat
statistical package (Jandel Scientiﬁc, San Rafael, CA, USA).
Association between any two variables was tested with
Spearman and Kendall Tau Correlation (Conover, 1980).
Multiple regression analyses were performed using forward
and backward regression models employing rank-transformed
data. Further regression analyses were conducted using a
negative binomial model in the Statistical Package for the
Social Sciences (spss; SPSS Inc., Chicago, IL, USA) for
Windows version 15 to account for overdispersion and
excessive zeros in the dependent variable, i.e. the number of
hospitalizations for pain in the designated 3-year period.
Results
Seventy plasma samples from SCD children aged 2–20 years
were evaluated; HbSS/HbSb
0thalassemia n = 48 including
n = 5 with HbSb
0thalassemia (henceforth referred to as HbSS
group), HbSC, n = 22; males = 37, females = 33. Clinical and
laboratory data were consistent with previously described
haematological parameters in children with SCD [WBC
and HbF: HbSS > HbSC; Haemoglobin: HbSS < HbSC
(P <0 Æ0001 in each case)] and hospitalizations for pain
HbSS > HbSC, P =0 Æ001 (Table I). (Of note, 45% of patients
had no episodes of pain, 30% of the patient cohort had >3 total
hospitalizations, and 7% had >9 total hospitalizations over the
3-year period). Similarly, baseline values of biomarkers were
greater in HbSS patients versus HbSC with regard to coagula-
tion activation [F1.2 (P =0 Æ017), DDimer (P <0 Æ001)],
haemolysis (LDH) (P <0 Æ001), and endothelial activation
[VCAM-1 (P =0 Æ027)], sP-selectin (P <0 Æ001) (Table II).
These results were also in keeping with previously published
data (Westerman et al, 1999; Setty et al, 2001, 2003; Mohan
et al, 2005; Blann et al, 2008; O’Driscoll et al, 2008).
Additionally, we also compared the distribution of hs-CRP
values in the study HbSS and HbSC populations to age- and
race-matched control ‘reference range’ hs-CRP data available
from a large population study (the National Health and
Nutritional Examination Study/NHANES – Ford et al, 2003).
A markedly higher median hs-CRP level was noted in the HbSS
group [n = 48, median CRP = 2Æ8 mg/l (1Æ04–5Æ6 mg/l, 25th–
75th percentile)], whereas median hs-CRP in the HbSC group
[n = 22, median CRP = 0Æ6 mg/l (0Æ3–1Æ2 mg/l, 25th–75th
percentile)] was similar to the NHANES control values
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as well as the smaller number of age-matched controls from
our study [n = 10, median CRP = 0Æ1 mg/l (0Æ05–0Æ5 mg/l,
25th–75th percentile)]. In 25 of the 70 patients, hs-CRP levels
were assayed on available plasma samples from at least two
different time points (ranging from 3 to 9 months apart).
Intra-individual variability for CRP levels in these 25 samples
was low, as evidenced by strong association between the pairs
of measurements by Kendall Tau rank correlation (s =0 Æ69;
P <0 Æ0001) and Spearman rank correlation (Spearman
r =0 Æ89, P <0 Æ0001; raw data and correlation graphs are
available in Table SI).
Analyses for correlations between biomarkers and VOC
related hospitalizations
In the SCD patient group as a whole, by univariate correlation,
all values except platelet count, sP-selectin and HbF showed
statistically signiﬁcant correlations with 3-year cumulative
hospitalizations for pain as the dependent variable (Table III).
In the group of patients with the more severe phenotype, the
HbSS group, univariate analysis demonstrated that inﬂamma-
tory biomarkers (hs-CRP and WBC) remained signiﬁcantly
positively correlated with hospitalizations for pain over the
3-year period. In addition, in accordance with prior studies,
HbF levels were ‘protective’, inversely correlating with hospi-
talizations only in the HbSS group, with the lack of correlation
in the total SCD cohort explained by the expected low mean
HbF level in HbSC disease. Of note, when hs-CRP values from
25 samples obtained from subjects at a different time point
than that used in the initial analysis were substituted and
re-analyzed, univariate correlations between 3-year cumulative
hospitalizations for pain and hs-CRP levels remained
unchanged. In the total SCD group Spearman r =0 Æ532 for
substituted CRP values versus r =0 Æ469 for original values; in
the HbSS group Spearman r =0 Æ472 for substituted CRP
values versus r =0 Æ391 for original values.
Multiple regression analyses (performed in the SCD group
as a whole with 3-year cumulative hospitalizations as the
dependent variable, and hs-CRP, sP-selectin, VCAM-1, LDH,
WBC and HbF as the independent variables) identiﬁed
associations only with hs-CRP and WBC which contributed
22% and 5% respectively, to the overall model. When data
from HbSS group alone were evaluated in the regression
Table II. Biomarker panel in children with SCD.
Biomarker
Total SCD





(n = 22) Controls
F1Æ2 (nmol/l) 1Æ06 (0Æ76–1Æ41) **1Æ22 (0Æ78–1Æ52) 0Æ84 (0Æ70–1Æ11) 0Æ73 (0Æ41–1Æ27) (n = 29)
D-Dimer (ng/ml) 97 (33–209) (n = 60) ***168 (88–290) (n = 38) 32 (32–80) 48 (32–88) (n = 29)
LDH (i/u per litre) 371 (268–504) ***449 (303–619) 272 (240–336) 246 (171–291) (n = 29)
sVCAM-1 (ng/ml) 748 (587–1004) *783 (610–1049) 628 (539–846) 538 (446–628) (n = 29)
sP-Selectin (ng/ml) 54 (45–63) ***58 (50–67) 45 (38–50) 40 (33–50) (n = 27)
hs-CRP (mg/l) 1Æ3( 0 Æ6–3Æ8) ***2Æ8(1Æ02–5Æ3) 0Æ6( 0 Æ3–1Æ2) 0Æ1(0Æ05–0Æ5) (n = 10)
Results presented are the median (25th–75th) percentile values. Biomarkers from HbSS are signiﬁcantly different from the respective HbSC levels at
*P =0 Æ027, **P =0 Æ017 and ***P <0 Æ001 as assessed by Mann–Whitney Rank Sum Test. Biomarkers from the age-matched HbAA controls are also
shown for comparison; these ranges are similar to those previously published from our laboratory and others. (Blann et al, 2008 et al, 2008 ; Mohan
et al, 2005; O’Driscoll et al, 2008; Setty et al, 2001, 2003; Westerman et al, 1999 respectively).
Table I. Haematological data and 3-year
cumulative hospitalizations for vaso-occlusive
crisis (VOC) data in children with SCD.
Total SCD






HbF (g/l) 74 (35–116) 80 (57–125Æ5)** 28 (16–42)
Haemoglobin (g/l) 91 (82–107) 85 (79–92)** 111 (105–115)
WBC count (·10
9/l) 11Æ3( 8 Æ4–13Æ1) 12Æ2 (10Æ4–14Æ8)** 7Æ8( 6 Æ0–9Æ9)
Platelet count (·10
9/l) 383 (292–450) 428 (361–524)** 294 (269–347)
Cumulative 3-year
hospitalizations for pain
1 (0–4) 1 (0–5)* 0 (0–1)
Values are presented as median (25th–75th) percentiles. Statistical differences in variables
between HbSS/HbSb
0Thal group and HbSC group are notated as **P <0 Æ0001 and *P =0 Æ001
(Mann–Whitney Rank Sum Test). A retrospective review was performed on individual patient
records for a discharge diagnosis of painful episode or VOC with and without associated diag-
nosis of acute chest syndrome (ACS). Painful episodes over a cumulative 3-year period including
the calendar year of the blood draw, the year previous to, and the year following date of blood
draw were included in the analyses.
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the overall association. These results were conﬁrmed with a
negative binomial regression model that identiﬁed age and
hs-CRP as the best ﬁt to these count data, predicting a 12%
increase in pain frequency for every year of age, and a 6Æ6%
increase in pain frequency for every 1 mg/l increase in hs-CRP
(Table IV). Thus hs-CRP showed the strongest statistical
association between a laboratory biomarker and an important
clinical endpoint – increased hospitalizations for pain –
highlighting its potential clinical relevance.
Correlations between hs-CRP and other biomarkers
evaluated
In the SCD group (Table V), hs-CRP showed an inverse
correlation with Hb, and a positive one with LDH, suggesting
that baseline haemolytic activity may be associated with
inﬂammation. The correlation of hs-CRP with WBC counts
further supported an increase in the baseline inﬂammation
status. In addition, hs-CRP correlated signiﬁcantly with
markers of coagulation activation (F1.2, D-Dimer), and
endothelial activation (sVCAM1 and sP-selectin), perhaps
underscoring the key role of inﬂammation in connecting
different pathological pathways in SCD. No association
between hs-CRP and fetal haemoglobin was noted in the
SCD cohort as a whole, while in the HbSS/Sb
0Thal patient
group the inverse correlation between CRP and HbF levels fell
short of statistical signiﬁcance in this study (r = )0Æ27;
P =0 Æ067).
Discussion
This study of children and adolescents with SCD showed that,
from a broad panel of steady-state biomarkers, the inﬂamma-
tory marker hs-CRP was the most signiﬁcant correlate of
hospitalizations for painful episodes. While markers of
increased haemolytic status, endothelial activation and coag-
ulation activation all correlated positively with VOC events by
univariate analysis, only the inﬂammatory markers hs-CRP
and WBC stayed in multiple regression models, and age and
hs-CRP provided the best ﬁt in negative binominal models.
These data showed that hs-CRP, a well- established inﬂam-
matory biomarker (Pepys & Hirschﬁeld, 2003), was strongly
associated with paediatric VOC, an important clinical end-
point of microvessel occlusion in SCD.
Table III. Biomarker correlations with 3-year
cumulative hospitalizations for vaso-occlusive







(n = 48) HbSC (n = 22)
Spearman rP Spearman rP Spearman rP
Hb )0Æ364 0Æ002 )0Æ082 0Æ58 0Æ053 0Æ81
HbF )0Æ037 0Æ75 )0Æ331 0Æ02 )0Æ307 0Æ16
WBC 0Æ406 <0Æ0001 0Æ286 0Æ04 )0Æ127 0Æ56
Platelets 0Æ170 0Æ15 0Æ036 0Æ81 )0Æ463 0Æ02
LDH 0Æ379 0Æ001 0Æ260 0Æ07 )0Æ079 0Æ72
sVCAM-1 0Æ282 0Æ01 0Æ190 0Æ19 0Æ313 0Æ15
sP-Selectin 0Æ198 0Æ10 Æ04 0Æ78 )0Æ344 0Æ11
F1Æ20 Æ249 0Æ03 0Æ058 0Æ69 0Æ341 0Æ11
D-Dimer* 0Æ360 0Æ005 0Æ09 0Æ58 0Æ217 0Æ32
hs-CRP 0Æ469 <0Æ0001 0Æ391 0Æ006 0Æ076 0Æ73
Correlations were analyzed using Spearman’s rank correlation test.
*D-Dimer values were obtained from 60 of the 70 patients with SCD and 38 of the 48 subjects
with HbSS/HbSb
0Thal.










Intercept 0Æ760 0Æ410 1Æ410 33Æ777 <0Æ001
Age 1Æ119 1Æ057 1Æ184 16Æ797 <0Æ001
hs-CRP 1Æ066 1Æ001 1Æ134 3Æ992 0Æ046
A negative binomial model was used to account for over-dispersion and excessive zeros in the
dependent variable, i.e. the cumulative number of hospitalizations for pain in the designated
3-year period. The goodness of ﬁt of negative binomial models was estimated by log likelihood
function. Age and hs-CRP provided the best ﬁt to these count data, predicting a 12% increase in
pain frequency for every year of age, and a 6Æ6% increase in pain frequency for every 1 mg/l
increase in hs-CRP.
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biomarker for low-grade systemic inﬂammation has been
intensely investigated for its predictive associations with
adverse outcomes in vascular diseases, such as cardiovascular
(Cook et al, 2006; Folsom et al, 2006) and peripheral arterial
disease (Vainas et al, 2005; Vidula et al, 2008). The penta-
traxin protein CRP is produced in the liver as part of the
acute phase reaction, in response to a host of pro-inﬂamma-
tory cytokines (Hurlimann et al, 1966; Moshage et al, 1988).
Circulating CRP levels are determined solely by its rate of
synthesis and thus reﬂect the presence and strength of
pathological stimuli that are present in the individual at the
time of evaluation (Vigushin et al, 1993). Barring elevations
in CRP that are associated with acute infections and
inﬂammation, CRP concentrations are generally stable, falling
within a characteristic range for each individual (Macy et al,
1997; Pepys & Hirschﬁeld, 2003). A subset analysis of 25
patients showed that we have reason to believe that SCD
patients evaluated at steady state will also demonstrate intra-
individual stability of hs-CRP levels, which would be reﬂective
of their baseline state of inﬂammatory response. CRP is
exceptionally stable in serum or plasma when stored at )70 C
and readily available immunoassays have been well validated
in population studies (Kimberly et al, 2003; Roberts, 2004).
While our results from a retrospective cohort study need to
be conﬁrmed in a prospective manner, the advantages of
studying a well-validated biomarker, such as hs-CRP, in SCD
are manifold.
Many studies have documented altered pro-inﬂammatory
cytokine levels in the plasma of SCD patients during both
steady-state and acute vaso-occlusive crisis (Bourantas et al,
1998; Duits et al, 1998; Pathare et al, 2003), but no consistent
pattern of cytokines involvement in SCD has emerged that
correlates with speciﬁc clinical outcomes. However, these
cytokines, in turn, could be responsible for driving the low-
grade or chronic inﬂammatory response, evidenced by the
presence of mild-moderate, baseline elevations of acute phase
reactants, such as CRP (Singhal et al, 1993). Two paediatric
studies found increases in baseline hs-CRP levels that correlate
with increased resting energy expenditure or the ‘hypermet-
abolic’ state in SCD (n = 12) (Hibbert et al, 2005), and
oxidant stress (n = 35) (Akohoue et al, 2007). Clinical data
from adult SCD patients also document baseline CRP eleva-
tions (Mohan et al, 2005). In one study, baseline elevations in
CRP in adult HbSS/Sb
0Thalassemia patients were correlated
with a ‘sickle severity index’ as compared to heterozygous
sickle beta thalassemia patients (Hedo et al, 1993; Makis et al,
2006). Taken together, these studies documenting steady-state
CRP elevations suggest the presence of an ongoing inﬂamma-
tory response during symptom-free ‘steady state’ periods. To
our knowledge, no data is available with respect to the
association of chronic inﬂammation with speciﬁc clinical
outcomes in paediatric SCD.
In this context, our retrospective study, involving a mod-
erate-sized paediatric SCD cohort and covering the age
spectrum of 2–20 years, provides strong support for the
association of chronic inﬂammation with acute VOC/pain
episodes. In the study cohort, baseline median hs-CRP levels
were increased compared to population-deﬁned age- and race-
matched control levels. More signiﬁcantly, hs-CRP levels
showed a strong statistical association by appropriate regres-
sion modelling procedures with an important clinical endpoint
– increased hospitalizations for pain. Typically, patients with
homozygous HbSS/HbSb
0Thal manifest the highest rate of
vasocclusive events, as corroborated by our ﬁndings. Our data
show that children with the more severe phenotype, HbSS/
HbSb
0Thalassemia, have signiﬁcantly higher baseline hs-CRP
levels than those with HbSC disease. This ﬁnding suggests that
the presence of ongoing ‘signiﬁcant subclinical’ inﬂammation
in HbSS/HbSb
0Thal patients perhaps puts them at greater risk
for experiencing acute vasocclusive events.
In the HbSS group (Table III), inﬂammatory markers
hs-CRP and WBC, were strongly associated with clinical
outcome of hospitalization for pain events, while markers of







(n = 48) HbSC (n = 22)
Spearman rP Spearman rP Spearman rP
Hb )0Æ56 <0Æ0001 )0Æ28 0Æ057 )0Æ42 0Æ05
HbF 0Æ10 0Æ41 )0Æ27 0Æ067 0Æ08 0Æ70
LDH 0Æ40 <0Æ0001 0Æ25 0Æ084 0Æ05 0Æ82
Platelets 0Æ27 0Æ025 0Æ02 0Æ912 )0Æ04 0Æ84
sVCAM-1 0Æ29 0Æ014 0Æ22 0Æ135 0Æ16 0Æ46
P-Selectin 0Æ48 <0Æ001 0Æ33 0Æ02 0Æ17 0Æ43
F1Æ20 Æ43 <0Æ001 0Æ33 0Æ022 0Æ32 0Æ15
D-Dimer* 0Æ63 <0Æ001 0Æ47 0Æ003 0Æ46 0Æ02
WBC 0Æ46 <0Æ001 0Æ21 0Æ157 0Æ18 0Æ43
Correlations were analyzed using Spearman’s rank correlation test.
*D-Dimer data was obtained from 60 of the 70 patients with SCD and 38 of the 48 subjects with
HbSS/HbSb
0Thal.
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activation (sVCAM1 and sP-selectin) were not associated with
the clinical outcome of hospitalization for pain events.
However, in the same patient subgroup (Table V), hs-CRP
showed excellent correlation with these latter markers (F1.2,
D-Dimer, and sP-selectin) perhaps underscoring the intersec-
tion of inﬂammation with multiple pathological pathways in
SCD. It is possible that some of these laboratory markers of
additional putative pathogenic pathways of SCD microvessel
occlusion are not as robust in clinical analyses because of
assay-related or phenomenological reasons. We suggest that
our data indicate the strength of hs-CRP as a laboratory tool to
assess not only chronic inﬂammation, but also, via its
associations with markers of other pathogenic pathways, to
reﬂect underlying endothelial and coagulation activation as
well, thus making hs-CRP a more biologically relevant marker
of SCD-related activity.
We also determined correlations of hs-CRP with other
biomarkers in the panel evaluated and found that hs-CRP
was not associated with fetal haemoglobin levels in our study
cohort (SCD r =0 Æ1, P =0 Æ41; HbSS/HbS/beta
0Thalassemia
r = )0Æ27, P =0 Æ067 – Table V). Overall, we found no
statistically signiﬁcant correlation between hs-CRP and
markers of hemolysis (LDH and Hb) in the HbSS group.
Lower HbF levels are known to be associated with higher pain
rates (Platt et al, 1994), and provide the rationale for the use of
HbF modulators to treat SCD-related pain. However, in the
Multi-Center Study of Hydroxycarbamide, Charache et al
(1995), noted that some patients had a clinical response even
before sustained elevation of HbF implying that HbF modiﬁers
like hydroxycarbamide can affect sickle cell anaemia by
mechanisms other than increase in fetal haemoglobin. We
submit that the lack of a clear association between HbF and
hs-CRP in our study perhaps gives credence to the involvement
of additional pathogenic mechanisms, such as inﬂammation,
in SCD vaso-occlusion.
In addition to being a retrospective analysis there are other
limitations to our study, which we have tried to address.
Though we do not have longitudinal data on the entire study
sample, in a subset analysis of 25 patients with two baseline or
steady state measurements ranging from 3 to 9 months apart,
we found strong short-term intra-individual correlation
between the two sample measurements. This provides us with
some basis to believe that SCD patients will also demonstrate
longitudinal stability of hs-CRP levels, though this needs to be
conﬁrmed in a larger sample. We have used a 3-year
cumulative hospitalization for pain centered upon the year
that plasma biomarker determinations were done. This is
because the frequency of pain hospitalizations, while relatively
consistent from year to year, is infrequent in any given year. An
overdispersed negative binomial model was used to conﬁrm
multiple regression results because the dependent variable
consisted of discrete hospitalization events that resulted in
sparse count data (excessive zeroes). Our cohort was also
skewed more toward younger children given our interest in the
development of SCD symptomatology from early childhood
through adolescence and young adulthood. However, we feel
that because of this unique data set, we have been able to
document hs-CRP elevations at a relatively young age in the
HbSS with potential future clinical consequences.
In summary, the present study demonstrated a strong
association between the inﬂammatory biomarker hs-CRP and
hospitalization for VOC events in paediatric SCD. We believe
these results highlight the clinical relevance of inﬂammation in
microvessel occlusive complications, and provide a basis for the
study of hs-CRP as a potential biomarker for predictive
modelling of clinical outcomes in paediatric SCD.Perhaps most
signiﬁcantly, these data culled from a moderate-sized cohort of
70childrenwithSCD,lendsupportfortheclinicalreconciliation
of strong experimental evidence for the role of inﬂammation in
SCD vasoocclusion, and provide a basis for the future trials of
primary or adjuvant anti-inﬂammatory therapies in SCD.
Acknowledgements
Supported by Grant #U54 HL-070585 from the National
Heart, Lung and Blood Institute, National Institutes of Health.
References
Akohoue, S.A., Shankar, S., Milne, G.L., Morrow, J., Chen, K.Y., Ajayi,
W.U. & Buchowski, M.S. (2007) Energy expenditure, inﬂammation,
and oxidative stress in steady-state adolescents with sickle cell ane-
mia. Pediatric Research, 61, 233–238.
Belcher, J.D., Bryant, C.J., Nguyen, J., Bowlin, P.R., Kielbik, M.C.,
Bischof, J.C., Hebbel, R.P. & Vercellotti, G.M. (2003) Transgenic
sickle mice have vascular inﬂammation. Blood, 101, 3953–3959.
Belcher, J.D., Mahaseth, H., Welch, T.E., Vilback, A.E., Sonbol, K.M.,
Kalambur, V.S., Bowlin, P.R., Bischof, J.C., Hebbel, R.P. &
Vercellotti, G.M. (2005) Critical role of endothelial cell activation in
hypoxia-induced vasoocclusion in transgenic sickle mice. American
Journal of Physiology. Heart and Circulatory Physiology, 288, H2715–
H2725.
Blann, A.D., Mohan, J.S., Bareford, D. & Lip, G.Y. (2008) Soluble
P-selectin and vascular endothelial growth factor in steady state
sickle cell disease: relationship to genotype. Journal of Thrombosis
and Thrombolysis, 25, 185–189.
Bourantas, K.L., Dalekos, G.N., Makis, A., Chaidos, A., Tsiara, S. &
Mavridis, A. (1998) Acute phase proteins and interleukins in steady
state sickle cell disease. European Journal of Haematology, 61, 49–54.
Burger, P.C. & Wagner, D.D. (2003) Platelet P-selectin facilitates
atherosclerosis lesion development. Blood, 101, 2661–2666.
Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B.,
Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of
hydroxyurea on the frequency of painful crises in sickle cell anemia.
Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell
Anemia. New England Journal of Medicine, 332, 1317–1322.
Cook, N.R., Buring, J.E. & Ridker, P.M. (2006) The effect of including
C-reactive protein in cardiovascular risk prediction models for
women. Annals of Internal Medicine, 145, 21–29.
Conover, W.J. (1980) Practical Non-Parametric Statistics, 2nd edn.
John Wiley and Sons, New York.
S. Krishnan et al
802 ª 2009 Blackwell Publishing Ltd, British Journal of Haematology, 148, 797–804Duits, A.J., Schnog, J.B., Lard, L.R., Saleh, A.W. & Rojer, R.A. (1998)
Elevated IL-8 levels during sickle cell crisis. European Journal of
Haematology, 61, 302–305.
Embury, S.H., Matsui, N.M., Ramanujam, S., Mayadas, T.N., Noguchi,
C.T., Diwan, B.A., Mohandas, N. & Cheung, A.T. (2004) The con-
tribution of endothelial cell P-selectin to the microvascular ﬂow of
mouse sickle erythrocytes in vivo. Blood, 104, 3378–3385.
Folsom, A.R., Chambless, L.E., Ballantyne, C.M., Coresh, J., Heiss, G.,
Wu, K.K., Boerwinkle, E., Mosley, Jr, T.H., Sorlie, P., Diao, G. &
Sharrett, A.R. (2006) An assessment of incremental coronary risk
prediction using C-reactive protein and other novel risk markers:
the atherosclerosis risk in communities study. Archives of Internal
Medicine, 166, 1368–1373.
Ford, E.S., Giles, W.H., Myers, G.L., Rifai, N., Ridker, P.M. &
Mannino, D.M. (2003) C-reactive protein concentration distribu-
tion among US children and young adults: ﬁndings from the
National Health and Nutrition Examination Survey, 1999–2000.
Clinical Chemistry, 49, 1353–1357.
Frenette, P.S. & Atweh, G.F. (2007) Sickle cell disease: old discoveries,
new concepts, and future promise. Journal of Clinical Investigation,
117, 850–858.
Frenette, P.S., Moyna, C., Hartwell, D.W., Lowe, J.B., Hynes, R.O. &
Wagner, D.D. (1998) Platelet-endothelial interactions in inﬂamed
mesenteric venules. Blood, 91, 1318–1324.
Hedo, C.C., Aken’ova, Y.A., Okpala, I.E., Durojaiye, A.O. & Salimonu,
L.S. (1993) Acute phase reactants and severity of homozygous sickle
cell disease. Journal of Internal Medicine, 233, 467–470.
Hibbert, J.M., Hsu, L.L., Bhathena, S.J., Irune, I., Sarfo, B., Creary,
M.S., Gee, B.E., Mohamed, A.I., Buchanan, I.D., Al-Mahmoud, A. &
Stiles, J.K. (2005) Proinﬂammatory cytokines and the hypermeta-
bolism of children with sickle cell disease. Experimental Biology and
Medicine, 230, 68–74.
Hurlimann, J., Thorbecke, G.J. & Hochwald, G.M. (1966) The liver as
the site of C-reactive protein formation. Journal of Experimental
Medicine, 123, 365–378.
Kato, G.J., Martyr, S., Blackwelder, W.C., Nichols, J.S., Coles, W.A.,
Hunter, L.A., Brennan, M.L., Hazen, S.L. & Gladwin, M.T. (2005)
Levels of soluble endothelium-derived adhesion molecules in
patients with sickle cell disease are associated with pulmonary
hypertension, organ dysfunction, and mortality. British Journal of
Haematology, 130, 943–953.
Kato, G.J., McGowan, V., Machado, R.F., Little, J.A., Taylor, J.t.,
Morris, C.R., Nichols, J.S., Wang, X., Poljakovic, M., Morris, Jr, S.M.
& Gladwin, M.T. (2006) Lactate dehydrogenase as a biomarker of
hemolysis-associated nitric oxide resistance, priapism, leg ulceration,
pulmonary hypertension, and death in patients with sickle cell
disease. Blood, 107, 2279–2285.
Kaul, D.K. & Hebbel, R.P. (2000) Hypoxia/reoxygenation causes
inﬂammatory response in transgenic sickle mice but not in normal
mice. Journal of Clinical Investigation, 106, 411–420.
Kimberly, M.M., Vesper, H.W., Caudill, S.P., Cooper, G.R., Rifai, N.,
Dati, F. & Myers, G.L. (2003) Standardization of immunoassays for
measurement of high-sensitivity C-reactive protein. Phase I:
evaluation of secondary reference materials. Clinical Chemistry, 49,
611–616.
Koenig,W.,Sund,M.,Frohlich,M.,Fischer,H.G.,Lowel,H.,Doring,A.,
Hutchinson, W.L. & Pepys, M.B. (1999) C-Reactive protein, a
sensitive marker of inﬂammation, predicts future risk of coronary
heart disease in initially healthy middle-aged men: results from the
MONICA (Monitoring Trends and Determinants in Cardiovascular
Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 99, 237–
242.
Macy, E.M., Hayes, T.E. & Tracy, R.P. (1997) Variability in the mea-
surement of C-reactive protein in healthy subjects: implications for
reference intervals and epidemiological applications. Clinical
Chemistry, 43, 52–58.
Makis, A.C., Hatzimichael, E.C., Stebbing, J. & Bourantas, K.L. (2006)
C-reactive protein and vascular cell adhesion molecule-1 as markers
of severity in sickle cell disease. Archives of Internal Medicine, 166,
366–368.
Miller, S.T., Sleeper, L.A., Pegelow, C.H., Enos, L.E., Wang, W.C.,
Weiner, S.J., Wethers, D.L., Smith, J. & Kinney, T.R. (2000) Pre-
diction of adverse outcomes in children with sickle cell disease. New
England Journal of Medicine, 342, 83–89.
Mohan, J.S., Lip, G.Y., Wright, J., Bareford, D. & Blann, A.D. (2005)
Plasma levels of tissue factor and soluble E-selectin in sickle cell
disease: relationship to genotype and to inﬂammation. Blood
Coagulation and Fibrinolysis, 16, 209–214.
Moshage, H.J., Roelofs, H.M., van Pelt, J.F., Hazenberg, B.P., van
Leeuwen, M.A., Limburg, P.C., Aarden, L.A. & Yap, S.H. (1988) The
effect of interleukin-1, interleukin-6 and its interrelationship on the
synthesis of serum amyloid A and C-reactive protein in primary
cultures of adult human hepatocytes. Biochemical and Biophysical
Research Communications, 155, 112–117.
O’Driscoll, S., Height, S.E., Dick, M.C. & Rees, D.C. (2008) Serum
lactate dehydrogenase activity as a biomarker in children with sickle
cell disease. British Journal of Haematology, 140, 206–209.
Pathare, A., Kindi, S.A., Daar, S. & Dennison, D. (2003) Cytokines in
sickle cell disease. Hematology, 8, 329–337.
Pepys, M.B. & Hirschﬁeld, G.M. (2003) C-reactive protein: a critical
update. Journal of Clinical Investigation, 111, 1805–1812.
Platt, O.S. (2000) Sickle cell anemia as an inﬂammatory disease.
Journal of Clinical Investigation, 106, 337–338.
Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O.,
Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease.
Life expectancy and risk factors for early death. New England Journal
of Medicine, 330, 1639–1644.
Powars, D.R., Chan, L. & Schroeder, W.A. (1989) The inﬂuence of fetal
hemoglobin on the clinical expression of sickle cell anemia. Annals of
the New York Academy of Sciences, 565, 262–278.
Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, III,
R.O., Schechter, A.N. & Gladwin, M.T. (2002) Cell-free hemoglobin
limits nitric oxide bioavailability in sickle-cell disease. Nature
Medicine, 8, 1383–1389.
Ridker, P.M., Hennekens, C.H., Buring, J.E. & Rifai, N. (2000)
C-reactive protein and other markers of inﬂammation in the pre-
diction of cardiovascular disease in women. New England Journal of
Medicine, 342, 836–843.
Roberts, W.L. (2004) CDC/AHA Workshop on Markers of Inﬂam-
mation and Cardiovascular Disease: Application to Clinical and
Public Health Practice: laboratory tests available to assess inﬂam-
mation–performance and standardization: a background paper.
Circulation, 110, e572–e576.
Setty, B.N., Rao, A.K. & Stuart, M.J. (2001) Thrombophilia in sickle
cell disease: the red cell connection. Blood, 98, 3228–3233.
Setty, B.N., Stuart, M.J., Dampier, C., Brodecki, D. & Allen, J.L. (2003)
Hypoxaemia in sickle cell disease: biomarker modulation and
relevance to pathophysiology. Lancet, 362, 1450–1455.
CRP in Sickle Cell Disease Vasocclusive Crises
ª 2009 Blackwell Publishing Ltd, British Journal of Haematology, 148, 797–804 803Singhal, A., Doherty, J.F., Raynes, J.G., McAdam, K.P., Thomas, P.W.,
Serjeant, B.E. & Serjeant, G.R. (1993) Is there an acute-phase
response in steady-state sickle cell disease? Lancet, 341, 651–653.
Stuart, M.J. & Nagel, R.L. (2004) Sickle-cell disease. Lancet, 364, 1343–
1360.
Vainas, T., Stassen, F.R., de Graaf, R., Twiss, E.L., Herngreen, S.B.,
Welten, R.J., van den Akker, L.H., van Dieijen-Visser, M.P.,
Bruggeman, C.A. & Kitslaar, P.J. (2005) C-reactive protein in
peripheral arterial disease: relation to severity of the disease and
to future cardiovascular events. Journal of Vascular Surgery, 42,
243–251.
Verma,S.,Szmitko,P.E.&Ridker,P.M.(2005)C-reactiveproteincomes
of age. Nature Clinical Practice. Cardiovascular Medicine, 2, 29–36.
Vidula, H., Tian, L., Liu, K., Criqui, M.H., Ferrucci, L., Pearce, W.H.,
Greenland, P., Green, D., Tan, J., Garside, D.B., Guralnik, J., Ridker,
P.M., Rifai, N. & McDermott, M.M. (2008) Biomarkers of inﬂam-
mation and thrombosis as predictors of near-term mortality in
patients with peripheral arterial disease: a cohort study. Annals of
Internal Medicine, 148, 85–93.
Vigushin, D.M., Pepys, M.B. & Hawkins, P.N. (1993) Metabolic and
scintigraphic studies of radioiodinated human C-reactive protein in
health and disease. Journal of Clinical Investigation, 91, 1351–1357.
Westerman, M.P., Green, D., Gilman-Sachs, A., Beaman, K., Freels, S.,
Boggio, L., Allen, S., Zuckerman, L., Schlegel, R. & Williamson, P.
(1999) Antiphospholipid antibodies, proteins C and S, and coagu-
lation changes in sickle cell disease. Journal of Laboratory and
Clinical Medicine, 134, 352–362.
Supporting information
Additional Supporting information may be found in the online
version of this article:
Table SI. Intra-individual variability of hs-CRP levels.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
S. Krishnan et al
804 ª 2009 Blackwell Publishing Ltd, British Journal of Haematology, 148, 797–804